Annual report pursuant to Section 13 and 15(d)

Significant Strategic Collaborations (Details Narrative)

v3.24.1
Significant Strategic Collaborations (Details Narrative) - USD ($)
 12 Months Ended
Mar. 17, 2023
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue   $ 2,539,986 $ 1,706,925
Research and development expenses   3,494,765 4,770,834
Prepaid expenses and other current assets   603,828 $ 556,094
Initial payment for research $ 78,000    
Prepaid expenses and other   $ 400,000  
Pharmsynthez [Member] | Series B Preferred Stock [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Warrants outstanding   1,500,000  
Pharmsynthez [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Percent ownership in Xenetic   3.40% 2.90%
Takeda [Member] | Royalty Revenue [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue   $ 2,500,000 $ 1,700,000
Catalent Pharma Solutions [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development expenses   2,500,000  
Prepaid expenses and other current assets   100,000 $ 300,000
Other assets   300,000  
Scripps Research [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development expenses 938,000    
Monthly payment $ 78,000    
Scripps Research [Member] | Scripps Agreement [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development expenses   $ 800,000